ePT--the Electronic Newsletter of Pharmaceutical Technology, Aug 18, 2011 - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

ePT--the Electronic Newsletter of Pharmaceutical Technology, Aug 18, 2011
News
Pfizer Discloses Potentially Improper Payments
By Amy Ritter
In its latest filing with SEC for the quarter ending July 2011, Pfizer indicated that it has voluntarily provided the SEC and DOJ with information concerning potentially improper payments made by Pfizer and Wyeth in connection with sales activities that took place outside of the United States.
China's SFDA Following Through on GMP Efforts
By Angie Drakulich
Since China's State Food and Drug Administration revised its GMPs last year, the agency has been making other improvements as well to improve the quality of its pharmaceutical manufacturing industry.
Murky Picture for Life-Science Financing in Second Quarter
By Patricia Van Arnum
The second quarter of 2011 presented a mixed picture of financing for the life-science sector, which includes the biotechnology and medical-device industries.
PhRMA Opposes Changes to Medicare Part D
By Erik Greb
PhRMA has released a statement expressing their opposition to laws that would alter Medicare Part D.
Bayer Joins TB Battle
By Stephanie Sutton
Bayer HealthCare has agreed to support the Stop TB Partnership in the fight against multidrug-resistant tuberculosis by making 620,000 tablets of the antibiotic moxifloxacin available to WHO.
Week of August 15, 2011: Xcelience Expands its Facility in Tampa, Fla.; Delta Pharma Names John Ebeid as VP of Outsourcing; and More
Xcelience Expands its Facility in Tampa, Fla.; Delta Pharma Names John Ebeid as VP of Outsourcing; and More.
Regulatory Roundup: FDA, Arkansas Sign Agreement to Enhance Regulatory Science
FDA, Arkansas Sign Agreement to Enhance Regulatory Science.

ADVERTISEMENT

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
26%
Oversee medical treatment of patients in the US.
13%
Provide treatment for patients globally.
11%
All of the above.
39%
No government involvement in patient treatment or drug development.
11%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Click here